OTHER RECEIVABLE	6 Months Ended
Jun. 30, 2024
OTHER RECEIVABLE
OTHER RECEIVABLE	NOTE 6: OTHER RECEIVABLE Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. The Company recorded $0.7 million and $1.5 million of grant income related to the CPRIT grant for the three and six months ended June 30, 2024, respectively. At June 30, 2024, the Company recorded $1.9 million of grant income receivable related to the CPRIT grant. Additionally, the Company recorded $0.2 million and $0.2 million of grant income related to the FDA and SBIR grants, respectively, for the three months ended June 30, 2024. The Company recorded $0.5 million and $0.4 million of grant income related to the FDA and SBIR grants, respectively, for the six months ended June 30, 2024. At June 30, 2024, the Company recorded $0.2 million and $0.2 million of grant income receivable related to the FDA and SBIR grants, respectively. In July 2024, the Company received payments of $0.2 million and $0.2 million from the FDA and SBIR grants, respectively.

OTHER RECEIVABLE

6 Months Ended

Jun. 30, 2024

NOTE 6: OTHER RECEIVABLE

Qualifying grant income earned in advance of cash received from grants is recognized as revenue and recorded as other receivable. The Company recorded $0.7 million and $1.5 million of grant income related to the CPRIT grant for the three and six months ended June 30, 2024, respectively. At June 30, 2024, the Company recorded $1.9 million of grant income receivable related to the CPRIT grant.

Additionally, the Company recorded $0.2 million and $0.2 million of grant income related to the FDA and SBIR grants, respectively, for the three months ended June 30, 2024. The Company recorded $0.5 million and $0.4 million of grant income related to the FDA and SBIR grants, respectively, for the six months ended June 30, 2024. At June 30, 2024, the Company recorded $0.2 million and $0.2 million of grant income receivable related to the FDA and SBIR grants, respectively.

In July 2024, the Company received payments of $0.2 million and $0.2 million from the FDA and SBIR grants, respectively.